Back

Small Molecule Degradation of the microRNA-21 Precursor Rescues Pathogenic Pathways in Cellular Models of Fibrosis

Wang, T.; Yang, X.; Li, Y.; Song, J. H.; Disney, J. L.; Garcia, J. G. N.; Disney, M. D.

2025-12-12 biochemistry
10.64898/2025.12.09.693244 bioRxiv
Show abstract

MicroRNAs (miRNAs) are short RNA molecules that bind to target mRNAs, resulting in translational repression and gene silencing. Overexpression of microRNA-21 (miR-21) is associated with various human diseases, including autosomal dominant polycystic kidney disease (ADPKD) and pulmonary fibrosis. In this study, a previously described heterobifunctional molecule, TGP-21-RiboTAC, that degrades the miR-21 precursor (pre-miR-21) in triple negative breast cancer cells was investigated in polycystic kidney cell lines and a lung fibroblast cell line. In the former, TGP-21-RiboTAC degraded pre-miR-21 and de-repressed of miR-21s downstream target, Programmed Cell Death 4 (PDCD4) and Peroxisome Proliferator-Activated Receptor alpha (PPAR), known drivers of ADPKD. The heterobifunctional molecule also inhibited cyst growth and rescued the metabolic alterations that occur in ADPKD. In the lung fibroblast cell line, MRC-5, TGP-21-RiboTAC also reduced pre- and mature miR-21 levels, rescued Transforming Growth Factor {beta} (TGF-{beta})-induced repression of SMAD Family Member 7 (SMAD7) and inhibited cell invasion. Collectively, these studies demonstrate the potential of targeted RNA degradation as therapeutic agents that retard the development of organ fibrosis.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.1%
17.7%
2
Scientific Reports
3102 papers in training set
Top 17%
6.4%
3
International Journal of Molecular Sciences
453 papers in training set
Top 0.8%
6.4%
4
Molecular Therapy
71 papers in training set
Top 0.5%
4.3%
5
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 0.6%
3.6%
6
PLOS ONE
4510 papers in training set
Top 42%
3.1%
7
eLife
5422 papers in training set
Top 31%
2.8%
8
Frontiers in Molecular Biosciences
100 papers in training set
Top 0.8%
2.5%
9
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 3%
2.4%
10
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.1%
2.1%
50% of probability mass above
11
Journal of the American Heart Association
119 papers in training set
Top 2%
2.1%
12
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.7%
13
ACS Omega
90 papers in training set
Top 2%
1.7%
14
The FASEB Journal
175 papers in training set
Top 1%
1.7%
15
Cells
232 papers in training set
Top 3%
1.3%
16
Aging Cell
144 papers in training set
Top 2%
1.2%
17
Journal of Cellular Physiology
21 papers in training set
Top 0.4%
1.2%
18
Journal of Biological Chemistry
641 papers in training set
Top 3%
1.1%
19
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 2%
1.0%
20
Cellular and Molecular Life Sciences
84 papers in training set
Top 0.4%
1.0%
21
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.0%
22
NAR Molecular Medicine
18 papers in training set
Top 0.1%
1.0%
23
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 41%
0.9%
24
JCI Insight
241 papers in training set
Top 6%
0.9%
25
EBioMedicine
39 papers in training set
Top 0.8%
0.9%
26
Nature Communications
4913 papers in training set
Top 59%
0.9%
27
American Journal of Physiology-Renal Physiology
25 papers in training set
Top 0.2%
0.8%
28
Frontiers in Immunology
586 papers in training set
Top 8%
0.8%
29
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.7%
0.8%
30
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.7%
0.8%